CRTX stock forecast

Yesterday, Cortexyme ( CRTX -0.21% ), a clinical-stage biotech, saw its shares drop by a whopping 76%. The drugmaker’s stock crumbled after the company announced that the experimental Alzheimer’s disease therapy, atuzaginstat, missed the co-primary endpoints of its phase 2/3 GAIN trial .

Cortexyme has received a consensus rating of Hold . The company’s average rating score is 2.17, and is based on 2 buy ratings, 3 hold ratings, and 1 sell rating.

PROFILE (CRTX) Cortexyme, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics . Its pipeline comprises COR388, COR588, COR788, COR822, and Coronavirus 3CL protease inhibitor. The company was founded by Casey Crawford Lynch, Stephen…

Out of 4 analysts, 0 (0%) are recommending CRTX as a Strong Buy , 1 (25%) are recommending CRTX as a Buy, 2 (50%) are recommending CRTX as a Hold, 1 (25%) are recommending CRTX as a Sell, and 0 (0%) are recommending CRTX as a Strong Sell. What is CRTX’s earnings growth forecast for 2022-2024?